GlassScriptPhysician profile
Jason Singh
NPI 1851667893
$1,025.11
in general payments reported to CMS, 2019-2025
11 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $47.60 · 2024: $481 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964 · Gift: $60.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.28 |
| Gift | $60.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.69 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $223.74 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.06 | 2024-2025 | Breztri, Airsupra |
| Kvk-Tech, INC. | $60.83 | 2025 | |
| Merck Sharp & Dohme LLC | $49.09 | 2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $45.97 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $31.89 | 2023 | Bexsero, Pediarix, Arexvy |
| Abbvie INC. | $23.01 | 2025 | |
| Exact Sciences Corporation | $19.28 | 2025 | The Cologuard Plus Collection Kit |
| Acella Pharmaceuticals, LLC | $17.58 | 2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $13.97 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.